SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending after the FDA signaled decisive action against non-approved compounded GLP-1 drugs, specifically mentioning companies like Hims & Hers for mass-marketing alternatives, leading to a referral to the Department of Justice. This has split the community, with some fearing severe repercussions and others seeing a buying opportunity, accusing "Big Pharma" of FUD.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is gaining traction as its community anticipates the upcoming 4/20, focusing on steady, culture-driven growth and destigmatizing cannabis through global legalization initiatives. Enthusiasts view it as a long-term holding on Solana, often comparing its potential to Bitcoin and highlighting its dedicated yet often private supporter base.

WorldFinancial

WLFI crypto is trending amid a U.S. House investigation into a $500 million investment deal with a UAE royal family member, fueling intense community debate over its future as a real-world asset tokenization platform and stablecoin, or whether its political ties make it a speculative "scam" subject to regulatory scrutiny.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. It provides online news services where users can select and rank web content. The firm also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit is actively discussed after delivering a strong earnings report and announcing a $1 billion share buyback, yet the stock experienced a significant post-earnings decline, leading to widespread community debate about potential market manipulation and whether it presents an undervalued buying opportunity amidst broader social media sector trends.

Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. It manufactures surgical and medical instruments using a novel and proprietary platform technology called Nano-Pulse Electro-Signaling. The NPES provides local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic apoptosis of the cells. The company was founded on May 19, 2014 and is headquartered in Miami, FL.

Pulse Biosciences Inc

Pulse Biosciences is trending due to recent positive clinical data from its nPulse cardiac catheter feasibility studies, demonstrating strong procedural success, coupled with critical FDA designations and clearances for its proprietary nsPFA technology. The community is highly optimistic about this "game-changing" medical technology and the significant insider ownership, anticipating further growth.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio is trending due to significant community debate surrounding the impending PDUFA date for its RGX-121 gene therapy, now complicated by an FDA clinical hold stemming from a detected brain tumor in a related trial. While many anticipate a Complete Response Letter and a sharp stock decline, a vocal segment emphasizes the company's long-term value, pointing to recently positive data from its Duchenne program (RGX-202) and a strong cash runway as reasons to buy the dip.

ETF Opportunities Trust - T-Rex 2X Inverse MSTR Daily Target ETF

T-Rex 2X Inverse MSTR Daily Target ETF

MSTZ, a 2x inverse ETF targeting MSTR, is experiencing a sharp, high-volume decline, signaling a strong upward move in MicroStrategy and its Bitcoin holdings that has severely impacted inverse positions. The community is lamenting significant losses and discussing the inherent risks of leveraged products amidst the ongoing debate about MicroStrategy's Bitcoin strategy.

Tidal Trust II - Defiance Daily Target 2X Long ORCL ETF

Defiance Daily Target 2X Long ORCL ETF

ORCX is trending with intense community discussion amid high volatility, as traders are sharply divided between those frustrated by recent declines and others aggressively buying the dip, betting on a strong rebound for the underlying Oracle ($ORCL) stock, driven by its AI initiatives and TikTok partnership.

The Mullen Army Token originated from a dedicated community of retail investors who faced challenges in the traditional stock market. We united to create a cryptocurrency that embodies our principles and aspirations for a fair financial system.     We provide a platform for retail investors to engage in a transparent and fair financial market. Our efforts include grassroots marketing, community engagement, and educational content to empower our investors.

MullenArmy

MullenArmy (MULN) is trending amidst fierce community debate, with proponents touting it as a "community takeover project" with "real-world utility" and potential for significant gains, while a strong opposing sentiment labels it a "scam coin" drawing parallels to the controversial history of Mullen Automotive stock, often citing concerns over market manipulation and "rug pulls."

SMX (Security Matters) Plc is a holding company, which engages in the provision of authentication solutions. It offers brand protection, authentication, and track and trace technology. The company was founded by Haggai Alon on July 1, 2022 and is headquartered in Dublin, Ireland.

SMX (Security Matters) Plc

SMX (Security Matters) PLC

SMX is trending after securing an extended $250 million Equity Line of Credit, which provides capital through 2028 without further dilution, igniting widespread community speculation for another historic short squeeze and multi-day parabolic run.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Polyrizon Partners With Clearmind To Advance Intranasal MEAI For CNS Disorders

(RTTNews) - Clearmind Medicine (CMND) announced that it has entered into a development agreement with Polyrizon to create a proprietary intranasal formulation of MEAI, a non-hallucinogenic...

Small Cap Stocks To Keep An Eye On - December 4th

SMX (Security Matters) Public, Spring Valley Acquisition, Direxion Daily META Bull 2X Shares, Polyrizon, and Direxion Daily TSLA Bear 1X Shares are the five Small Cap stocks to watch today, according...

Top Biotech Stocks To Consider - December 4th

Danaher, Polyrizon, Vertex Pharmaceuticals, Medpace, Abivax, Capricor Therapeutics, and Moderna are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech...

Polyrizon Stock Skyrockets After New Data Shows Naloxone Gel Outperforms Marketed Spray

Polyrizon stock is up on new data showing its naloxone hydrogel formulation has stronger and longer-lasting mucosal retention.read more...

What Sparked Polyrizon's (PLRZ) 140% After-Hours Stock Surge?

Polyrizon surged in nearly 140% after-hours trading following preclinical data showing its naloxone hydrogel outperforms a marketed spray and a key manufacturing milestone.read more...

Polyrizon Hits Key Breakthrough That Brings Its Nasal Spray Closer To 2026 Trials

Polyrizon jumps over 100%. The company completes major manufacturing milestone for its proprietary nasal-spray product platform.read more...

<ul class="summary-bullets"><li>The expanded production ensures that the PL-14 spray can be reliably manufactured at higher volumes.</li><li>Following the update, Polyrizon’s stock traded over 82% higher in Tuesday’s premarket.</li><li>The upscaled process is designed to provide clinical trial material (CTM) for studies scheduled to begin in 2026.</li></ul>Polyrizon (PLRZ) announced on Tuesday a major manufacturing milestone for its proprietary nasal spray platform, bringing the company closer to supporting upcoming clinical trials and potential commercial availability.Following the update,&nbsp;<a href="https://stocktwits.com/symbol/PLRZ">Polyrizon’s stock</a> traded over 73% higher in Tuesday’s premarket. On Stocktwits, retail sentiment for the stock improved to ‘extremely bullish’ from ‘bullish’ territory, amid ‘high’ message volumes.&nbsp;<h2 class="st-heading-2">Milestone Achievement</h2>Polyrizon successfully scaled its production process from small laboratory batches to larger, controlled manufacturing runs, validating the key parameters of its PL-14 formulation.&nbsp;The expanded production ensures that the PL-14 spray can be reliably manufactured at higher volumes while maintaining the quality standards necessary for clinical trials.<blockquote>"The process validated our manufacturing strategy.”&nbsp;-Tomer Izraeli, CEO, Polyrizon&nbsp;</blockquote>“With this batch in hand, we are energized and prepared to advance into next batches towards clinical trial material manufacturing, which we believe brings us one step closer to addressing the unmet needs in the nasal spray market."<h2 class="st-heading-2">Preparing For Clinical Trials</h2>The upscaled process is designed to provide clinical trial material (CTM) for studies scheduled to begin in 2026. Polyrizon’s manufacturing procedures align with theU.S. and European regulatory requirements.The PL-14 nasal spray is engineered to create a fast-acting, moisturizing barrier in the nasal cavity, helping trap, isolate, and neutralize airborne allergens before they contact mucosal tissues. Developed using Polyrizon’s proprietary Capture &amp; Contain (C&amp;C) bio-adhesive technology, the spray offers extended, non-pharmacological protection for people exposed to high levels of environmental allergens.&nbsp;PLRZ stock has lost over 99% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/mongodb-stock-rises-premarket-as-analysts-increase-price-targets/cLIajIsRE0t">MongoDB’s Atlas Engine Drives A Wave Of Price Target Hikes – Stock Pops In Premarket Trade</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Why Did Polyrizon Stock Soar Pre-Market Today? 

Polyrizon successfully scaled its production process from small laboratory batches to larger, controlled manufacturing runs, validating the key parameters of its PL-14 formulation. 

Equity

Polyrizon successfully scaled its production process from small laboratory batches to larger, controlled manufacturing runs, validating the key parameters of its PL-14 formulation. 


Polyrizon Ltd (PLRZ)&nbsp;led the pack with a 23% increase in weekly followers after the development-stage biotech company dropped plans to undergo a 1-for-10 reverse stock split, which led to shares surging nearly fourfold on Friday.The Israel-based company specializes in preventing biological threats, including allergens and viruses, from penetrating mucosal tissues — an area that has gained new relevance in the post-COVID-19 world.Last month, Polyrizon reported promising preliminary safety results for its&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/plrz-stock-surges-on-manufacturing-deal-for-trial/cJaVyHWR1U">PL-14</a> Allergy Blocker, a mucoadhesive nasal gel spray designed to create a physical barrier against airborne allergens. The company expects to launch clinical trials in the U.S. and Europe by late 2025 or early 2026.Polyrizon stock has lost over half its value this year.Pheton Holdings (PTHL)&nbsp;saw a 19% rise in retail follower growth over the past week despite the absence of any news catalyst.The Beijing, China-based healthcare solution provider specializes in treatment planning systems for brachytherapy and other related products and services.The company's shares debuted on the Nasdaq in September 2024 and have gained a little over 4% since. However, their performance has been less than stellar year to date, with a loss of over 5%.AirSculpt Technologies (AIRS)&nbsp;posted an 8% jump in weekly Stocktwits follower additions. The body contouring specialist reported better-than-expected quarterly results and forecast full-year revenue of about $160 million to $170 million, which topped Wall Street estimates.Shares of the Miami Beach, Florida-based company, which offers minimally invasive fat removal procedures, have lost over 42% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Polyrizon, Pheton, AirSculpt: Top 3 Healthcare Stocks With Soaring Weekly Retail Interest

A trio of small-cap healthcare stocks caught the attention of retail investors last week, posting sharp jumps in follower growth on Stocktwits. 

Shares of Polyrizon skyrocketed more than 200% to an all-time high on Wednesday, making it the top biotech stock with the most new followers on Stocktwits in the past 24 hours.&nbsp;Trading volume surged 890 times the daily average, reflecting heightened investor interest in the Israel-based biotech company.The massive rally follows Polyrizon’s announcement of a manufacturing agreement with Eurofins CDMO Amatsiaquitaine, a prominent European Good Manufacturing Practice (GMP) manufacturer.&nbsp;This collaboration will supply clinical trial material for Polyrizon’s experimental allergy blocker, PL-14, which is set to enter clinical trials in 2025.The PL-14 allergy blocker is part of Polyrizon’s effort to develop innovative nasal sprays that create a hydrogel-based shield in the nasal cavity, protecting against allergens and viruses.&nbsp;The manufacturing deal secures a compliant supply chain for the clinical trial, marking a key milestone for the development-stage biotech firm.Retail chatter on Stocktwits has been overwhelmingly bullish.<stembedurl>https://stocktwits.com/TraderUKBoyy/message/597012617</stembedurl><stembedurl>https://stocktwits.com/Dollarpee/message/597017164</stembedurl>Polyrizon’s stock had a rocky start on the Nasdaq, debuting at the end of October with a disappointing IPO.&nbsp;The company priced 958,903 units at $4.38 per unit, with each unit including one ordinary share and three warrants exercisable at the same price. Shares dropped more than 64% post IPO.Despite the poor debut, Polyrizon has gained 90% so far this year following Wednesday’s surge, although it remains below its IPO price.&nbsp;Over the past month, the stock has seen a meteoric rise in popularity, adding 1,576% more followers on Stocktwits amid a 10,300% spike in message volume.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stockbroker analyzing financial stock market with reflection on eyeglasses. Photo via Westend61 on Getty Images

Polyrizon's Retail Following Booms As Biotech Stock Triples On Manufacturing Deal For Allergy Blocker Trial

This collaboration will supply clinical trial material for Polyrizon’s experimental allergy blocker, PL-14, which is set to enter clinical trials in 2025.

Polyrizon Ltd. is a development stage biotech company, which engages in the development of nasal hydrogels. It provides barriers from the interaction of biological assaults, including a new strain of coronavirus, influenza, allergens and other airborne pathogens with the nasal epithelial tissue. The company was founded by Tomer Izraeli in January 2005 and is headquartered in Raanana, Israel.

Polyrizon Ltd.

Up 5%

Down 5%

Markets are hovering near key levels, making the next 5% move especially important for sentiment. A breakout higher could reinforce the bull case, while a 5% drop may signal rising risk and tighter conditions. Which comes first?

Current Price	$12.85
Prev Close	$12.43
Open	$12.52
Dividend Yield	0.00%
50-Day Moving Average	$11.28
Beta	-1.14
Avg. Volume	154,605.20
PE Ratio	-0.04

52-Week High	$2,235.00
52-Week Low	$2.88
Market Capitalization	$19.81M
EPS (Annual)	-$552.51
Price to Book	0.66
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

PLRZ
Polyrizon Ltd. Ordinary Shares

Feed

News

Sentiment

Fundamentals

Info

Latest PLRZ News

PLRZPolyrizon Ltd. Ordinary Shares